Skip to main content

Life Sciences

Going Up

Skyscraper is not a commonly used term in Switzerland. Few buildings earn that moniker in a country that has mostly eschewed anything high-rise other than the Alps.


That will soon change as construction is commencing on the shell of Roche’s Building 1 in Basel, which, when completed in 2015, will be Switzerland’s tallest building at 178 meters (584 ft.).


The 41-story tower, which will rule Basel’s skyline, will be the city’s tallest by a wide margin. Basel currently has just one building taller than 20 stories, the 32-story Basler Messeturm office building. For the pharmaceutical giant Roche, the new tower is about consolidating offices currently scattered around the city.


“Roche needs a new office building in Basel,” Roche CEO Severin Schwan said when the project was announced in late 2009. “We are convinced that having all the company’s departments — research, development, production, marketing and corporate — close to each other will be crucial in ensuring that they work together successfully.”


Roche is investing CHF 550 million (US$604 million) in Building 1, which will be home to 2,000 Roche employees. Excavation work on the foundation pit began last spring. Shell construction will begin in March and continue through the end of 2014. Interior fit-out work will take place simultaneously, starting in 2013. Roche plans to move into the building at the end of 2015.


Building 1, sometimes referred to as the Roche Tower, is being designed by the renowned Basel architectural firm Herzog & de Meuron, whose most famous project is Bird’s Nest stadium, built for the 2008 Beijing Olympics. The Roche building, which will have 71,900 sq. m. (774,363 sq. ft.) of gross floor space, will feature earthquake-resistant construction and will be built to strict Swiss Minergie energy standards.


“Building 1 is a clear commitment of Roche to the Basel site as its corporate headquarters,” said Matthias M. Baltisberger, head of Roche’s Basel site. “We will create attractive workplaces that are conducive to dialogue and exchange, and offer a top-quality infrastructure to our employees.”


Herzog & de Meuron describe the structure as having a “distinctive wedge-shaped form,” slanting down towards the west and almost vertical to the east. The building is vertically structured by superimposed floor slabs of varying sizes, which are sculpturally expressed on the exterior by horizontal white parapet bands, according to the architects. Because of its geometry, Building 1 looks entirely different depending on the angle of view, making it a recognizable landmark for each part of the city from which it is seen.


Building 1 will include a 500-seat auditorium. Offices and meeting rooms are located from the fifth floor upward. The top floor features a cafeteria with views of Basel and the surrounding area.


The tower is just the latest Basel expansion for Roche. In November, the company inaugurated its new CHF 250-million (US$275-million) R&D building. The facility focuses on investigation and development of pharmaceutical formulations for new active ingredients, as well as manufacturing supplies for global clinical trials.


“Finding the safest and most efficient formulation for an active ingredient is a key part of the drug development process,” said Roche CEO Schwan. “Functions from the entire pharmaceutical value chain are located in Basel. This investment further strengthens the role of Basel headquarters and as a global center for research and development.”


In June 2011, Roche opened its new administrative center in Rotkreuz in the canton of Zug. It is the sixth new building to be constructed at the site in the past five years. The new 16-story, CHF 90-million (US$99-million) building will be home to 600 employees, and will bring together all the administrative departments attached to the various diagnostics business units at the site.

Life Sciences

Going Up

ContraFect is a biotech company pioneering the use of monoclonal antibodies and lysins (enzymes that digest the key component of bacteria, the cell wall) to treat life-threatening infectious diseases including MRSA and viruses such as influenza. The fledgling company, which moved to Yonkers, N.Y., in late 2010, has ambitious expansion plans at its new headquarters, which formerly housed Otis Elevator’s manufacturing operations.

“We started as a virtual company in a small office in Manhattan with a couple of people,” says Dr. Robert Nowinski, ContraFect’s founder, chairman and CEO. Nowinski previously founded four biotech companies in the Seattle area which were ultimately acquired by large pharmaceutical companies.

Nowinski says while he is pleased with ContraFect’s location, the company nearly wound up in Virginia.

“At the same time we looked at Yonkers, we were talking with a colleague in Virginia and were invited to come to Virginia to discuss our company,” Nowinski says. “They were associated with George Mason University. The university became interested in offering us an opportunity for some space if we were willing to move the research elements of our company to Virginia. The initial plan was to create a research institute in Virginia, which would have had our company within that as one of the founders of a public-private institute on the George Mason campus.”

The Virginia Legislature subsequently allocated funds for the institute, but the proposal evolved into something larger than originally planned. That caused ContraFect to re-think its position.

 “The money was approved in Virginia, but as we began to put together a program, a desire developed in the Virginia Legislature to diversify the institute into not just ourselves and George Mason, but several other universities,” Nowinski says. “As this became more complex, we began to see this as not as easy a task as we had anticipated.”

At that point, ContraFect began reconsidering the issue of space in New York. Nowinksi returned to Yonkers to meet with Joe Cotter, founder and president of National RE/sources Group, which includes the i.park portfolio of redeveloped industrial properties. The Hudson i.park is a 24-acre (2.2-hectare) technology park in the Yonkers Waterfront District at the Yonkers Train Station. Discussions focused on the cost to build there, rent and tenant improvements.

“We are in a building that is the former Otis Elevator manufacturing plant, which is almost 100 years old,” Nowinksi says. “It’s a brick building that is scooped out and stands as the basic structure. As things became more complicated in Virginia, we became more interested in Yonkers, and we eventually worked out a plan with the landlord. We also completed a financing arrangement that enabled us to go forward with a larger facility than expected. We simultaneously formed other alliances in New York that suggested we would need larger lab space than initially anticipated.”

Nowinski says the combination of a good arrangement with i.park and the opportunity for extensive collaboration with a New York City medical school brought Yonkers back into serious consideration. Another plus was that the building was already home to another life sciences company, Aureon Biosciences.

“We were introduced to the Yonkers economic development group and then the mayor, and in a short period of time, they began to offer various indications of assisting us,” Nowinski says. “We made our decision to keep the company intact and that Yonkers would be where we would come.”

ContraFect currently occupies 15,000 sq. ft (1,393 sq. m.) and employs 30. Nowinksi anticipates leasing another 22,000 sq. ft. (2,043 sq. m.) within the next several weeks. That space comes from Aureon, which filed for bankruptcy and closed in October. ContraFect also has an option on 17,500 sq. ft. (1,625 sq. m.). Nowinski expects employment to be around 45 by the end of 2012.

Nowinski says ContraFect, which was formed in late 2008, will soon be going into FDA trials with its first product. Manufacturing will initially be outsourced, but he plans to bring that process in house as the first product or two comes to market.

“The biotech industry in New York has developed relatively late,” Nowinski says. “We are starting to see some growth here. Space is opening up in Manhattan with some of the large pharmaceuticals taking space to do biotech research in association with the universities there. Most of the smaller companies appear to be going into Westchester County or other areas surrounding Manhattan. We are very pleased to be in Yonkers. Ultimately we were able to get the type of space we needed, we were able to get the personnel we needed from the New York City area, which is an enormous recruiting location, and we have access to our collaborators in Manhattan.”

Online Insider

Going Up?

by Adam Bruns

The sun rose on October 6 over Charleston, S.C., just like it does every day, a little after seven o’clock in the morning. By the time it set at nearly seven that night, everything had come up sevens for South Carolina, and the state’s project portfolio was a billion dollars richer.

That’s because that propitious day saw the opening of DuPont’s new $500-million, 200,000-sq.-ft. (18,580-sq.-m.) Cooper River Kevlar plant, just north of Charleston, as well as the announcement that Continental Tire the Americas (CTA) will construct a $500-million plant in Sumter County, just east of Columbia, that will employ more than 1,600 people. CTA will also invest $4 million and add 80 jobs at its headquarters in Lancaster County, just south of Charlotte, where the company already employs nearly 350.

DuPont’s global production of Kevlar will immediately increase by 25 percent because of the new plant. That increase could reach 40 percent over the next two years.

“As the global population grows, there will be even more critical need for protection materials to keep people safe and to protect the environment, structures and critical processes,” said Thomas G. Powell, president, DuPont Protection Technologies, which had sales of $3.4 billion in 2010. “After more than 40 years, the proven performance of Kevlar continues to create significant new opportunities where the combination of lightweight strength and other unique properties enable new designs, increase reliability and save more lives.”

The project will create 135 jobs at the company, which recently invested $50 million in its Spruance Kevlar plant in Richmond, Va., where commercial production of the aramid fiber first began in 1971. DuPont also makes Kevlar at a facility in Maydown, Northern Ireland, and at a DuPont joint venture, DuPont-Toray Company, located in Tokai, Japan.  In addition, DuPont has R&D facilities and customer applications centers for Kevlar in Shanghai; Hyderabad, India; Paulina, Brazil; Meyrin, Switzerland; Richmond and in its hometown of Wilmington, Del.

Initial production at Cooper River will focus on three Kevlar technology platforms that support growing applications in sectors as diverse as ballistics, other personal protective equipment (see “NFL quarterbacks”), aerospace, tires, fiber-optic cables, oil and gas and automotive.

The project was originally announced in December 2007 with a planned start-up date in 2010. Asked about the delay, William Weber, vice president of DuPont Protection Technologies, North America, says via email, “We did have a delay, but the project continued, though at a slower pace due to the economic conditions in ’08-’09.”

At the same time, DuPont was pursuing an industrial espionage case over trade secrets related to Kevlar against Korean concern Kolon, a case that was just decided earlier this month in DuPont’s favor by the U.S. District Court for the Eastern District of Virginia in Richmond, a decision carrying with it an award of $919 million. Kolon is appealing the verdict.

As documented by IndustryWeek earlier this year, the company picked Berkeley County from among 40 possible sites worldwide, and chose it based on work force quality, good relationships with the county and state and “the ability to protect ‘very sensitive and very advanced’ technology used to produce new generations of Kevlar.”

Asked if the legal case against Kolon influence in any way the Cooper River project’s timeline or physical design with regard to security and trade secret protection, DuPont’s Tom Powell says, “The legal case had nothing to do with the timeline or the plant itself. The two are totally unrelated.”

That said, while media covered the ribbon-cutting at the site, they were kept away from key operational areas of the plant. That’s in keeping with business as usual at DuPont.

“We have high standards for protection of trade secrets and proprietary information at all DuPont sites, and Cooper River was constructed to those same standards,” explains Powell. “DuPont has a very active and rigorous trade secret protection program that we have implemented at all our offices and plant sites.  For years we’ve had restrictions on access to our sites and those same standards are applied globally.”

“The lawsuit stemmed from Kolon’s hiring of former DuPont employees from our Spruance site and from a joint venture in Japan in order to gain access to DuPont’s trade secrets for making Kevlar,” he continues. “The U.S. jury found that Kolon had improperly acquired and used DuPont’s confidential and trade secret information in large part by hiring the former DuPont employees as consultants. In doing so, Kolon attempted to bypass legitimate research and development and develop its business using stolen proprietary information to improve its own products and processes.”

Continental Intrigue

Among the strong prospects identified by DuPont as Kevlar sales opportunities is the $90-billion global tire business. Might the new plant find some new business just up the road in Sumter County, where CTA’s new tire plant will pump out 5 million tires a year by 2017 and aims to reach 8 million tires a year by 2021?

DuPont spokesperson Cathy Andriadis says the company rarely reveals customer names, though it has in the past served the needs of Boeing, whose new plant is ramping up just down the road in North Charleston. Several Continental Tire products containing Kevlar are prominent on the Web, most of them intended for bicycles and motorcycles. However, most citations are unclear as to whether their use of the word “Kevlar” is referring to the patented DuPont technology or is more generic in nature in referring to an aramid fiber. “Kevlar” is not found in a search of the Continental Web site, though a Continental brochure, without naming a brand, cites aramid fiber bead reinforcement on passenger tire products.

Continental’s new greenfield plant comes on the heels of its recent expansion in Mt. Vernon, Ill. CTA has seen a nearly 20-percent increase in total volume for the passenger and light truck tire business in the Americas region in the past two years.

“Increasing demand for Continental and General brand passenger and light truck tires in the U.S., as well as the improved business results for CTA, has made this significant investment possible,” said Nikolai Setzer, member of Continental’s Executive Board and head of Continental’s global tire business, on October 6. “On behalf of the 160,000 employees of Continental, I would like to offer our sincere thanks to Governor [Nikki] Haley, the state of South Carolina, the South Carolina Ports Authority and Sumter County.”

“South Carolina offered us the most compelling business climate that allows us to create these well-paying jobs with competitive benefits for the people of this great state,” said Jochen Etzel, CEO of Continental Tire the Americas.

“Today’s announcement further strengthens South Carolina’s membership in the automotive club,” said South Carolina Secretary of Commerce Bobby Hitt. “This is also the fourth announcement this year involving the recruitment of 500 or more jobs.” The company aims to create the 1,600-plus jobs by 2020.

The tire plant’s hundreds of jobs could very well have landed in North Carolina, but for some internal political and ethical wrangling. As recounted in multiple reports by the Associated Press, the land North Carolina was proposing for the project — at the Mid-Atlantic Logistics Center in Brunswick County — belongs to a Democratic state legislator and political donors who had given more than $52,000 to Gov. Beverly Perdue’s campaigns. In addition, the law firm hired by CTA to work on project negotiations employs Perdue’s son as a lawyer and site selection consultant.

Republican Senate leader Phil Berger labeled in “pay-to-play politics,” while Perdue countered that Berger “is making reckless accusations in order to evade responsibility for his own decision, a decision that cost North Carolina 1,300 jobs.” The North Carolina incentive package totaled nearly $100 million. Among the details in the AP account was the assertion, backed by documentation, that CTA demanded a $45-million cash payment, in the form of a “forgivable loan,” as part of its desired incentive package.

Back in South Carolina, the new 1-million-sq.-ft. (92,900-sq.-m.) manufacturing facility will be located on 330 acres (134 hectares) just off U.S. Highway 521 in Sumter County.

“Somehow the word ‘big’ just doesn’t seem big enough,” said Sumter Development Board Chairman Greg A. Thompson. “In a matter of a few short years, this new facility will go from an idea to one of the largest economic drivers in our community. At more than $500 million, it’s the largest industrial investment the county has ever seen.”

The Sumter County Coordinating Council approved a $31-million grant for purchase of and improvements to the site. The project was also awarded a $4 million federally funded Community Development Block Grant through Sumter County to offset costs associated with road and public infrastructure improvements.

Meanwhile, CTA’s headquarters investment way up in Lancaster County will provide for a 16,000-sq.-ft. (1,486-sq.-m.) addition, bringing the total size of the building to 91,000 sq. ft. (8,455 sq. m.).

Getting In On the Ground Floor

If that growing HQ needs some new elevators, there’s yet another new manufacturing plant coming to the Palmetto State that might be happy to oblige.

On September 15, Los Angeles-based REIT Hackman Capital announced that Otis Elevator Co., a business of Connecticut-based United Technologies, purchased the Florence Industrial Center property owned by its affiliate in Florence. The 423,581-sq.-ft. (39,351-sq.-m.) Class-A industrial facility, once occupied by Maytag, is situated on 49 acres (20 hectares) and also includes 35 acres of vacant land with Interstate frontage.

“Adjacent to Interstate 95 and in close proximity to deep-water seaports, Florence Industrial Center offers Otis a prime Southeastern location and first-rate building amenities for manufacturing and distribution,” said Michael Hackman, founder and CEO of Hackman Capital. The release also mentioned that Otis itself “has not yet shared specific details,” though it shared details all its own: “Jobs will come from Otis operations in other U.S. cities, and in Mexico, according to Florence County Economic Development Corporation officials, who anticipate a formal announcement from Otis later this month,” said Hackman.

Perhaps stoked — if not a trifle provoked — by the Hackman release, Otis got around to releasing its own announcement the very next day, saying the project would consolidate much of the company’s North American new equipment operations and bring more than 360 jobs to South Carolina.

“Our new facility in South Carolina will become Otis’ manufacturing center of excellence for the U.S. and Canada,” said Didier Michaud-Daniel, president of Otis, whose next most recent elevator manufacturing expansion was in Bangalore, India.

The Florence facility will produce all new energy-efficient elevators that have not been produced anywhere else in North America. The site will feature a 150-ft. test tower, and will include manufacturing, engineering, a contract logistics center and field support operations. “The co-location of these functions, currently situated in four different cities, will reduce lead times improving both speed to market and the customer experience,” said the company.

Hackman Capital said it had renovated and completely rebranded the property in June of 2009, after selling and removing approximately 100 pieces of specialized Maytag equipment. It then offered deal details that Otis did not:

“Otis completed a fee-in-lieu-of (FILO) payment agreement with Florence County, in an economic development project known as Project Rosebud, last month, in which the county agreed to dramatically reduce Otis’ property taxes over the next 30 years,” the Hackman release stated. “For its part, the company is contracted to bring at least 360 jobs with an average wage of $25 per hour to the site and invest a minimum of $40 million in capital. If the company doesn’t meet those benchmarks in the prescribed amount of time the local incentives agreement will be wholly or partially cancelled.

“Beyond the tax rate reduction, an additional incentive offers Otis a $1,000 cash grant from the county for every Florence County resident who is employed at the site for at least three years up until December 31, 2016,” the release continued. “That grant for up to 400 employees means a potential local grant of $400,000. The average salary of the employees counted must also be $25/hour, although that can include bonuses.”

The complex is expected to begin operations during the second quarter of 2012.